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EFFECTS OF VARYING THE CONCENTRATION OF LOCALLY ADMINISTERED
5-FLOIJROURACIL ON BASAL CELL CARCINOMA*
HOWARD L. STOLL, Js., MD., EDMUND KLEIN, M.D.
AND ROBERT CASE, B.S.t
In previous studies (1, 2, 3, 4, 5, 6, 7) local
administration of 5-Fluorouracil' (5-FL) was
found to have a marked effect upon the natural
course of single and multiple basal cell cpithe-
liomas and solar keratoses as well as secondary
tumors in the skin. The variables that ap-
peared to influence the effects of 5FU and other
topically administered antimitotic agents upon
the tumors included: concentration of the
agent; use of occlusive dressings; duration of
application and nature of the vehicle contain-
ing the agent. Comparisons of the effects of
preparations containing various concentrations
of 5-FL upon large confluent areas of superficial
basal cell epitheliomatosis have been reported
(3). This report presents a more systematic
study to compare the effects of different con-
centrations of 5-FU concurrently administered
by inunction to multiple, superficial, basal cell
carcinomas in the same patient.
METHODS
In this study, 5 patients with multiple basal cell
carcinomas were investigated. Two patients, a 39
year old white female (E.C.) and a 49 year old fe-
male (MG.) had widespread multiple basal cell
carcinomas associated with the basal cell ncvus
syndrome. The third patient was an 86 year old
white female (B.L.) with multiple superficial basal
cell carcinomas of the trunk and lower extremities
of unknown etiology. The fourth patient was a 46
year old female (MS.) with multiple basal cell
carcinomas of the face, trunk and hmbs. Twenty-
five years ago she had received multiple incre-
ments of x-ray therapy to the face, neck, shoulders,
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chest and legs for hypertricnosis. The fifth patient
was a 58 year old white male (A.B.) with multiple
basal cell carcinomas of the neck, trunk and upper
arms, who had received x-ray therapy for cystic
acne 20 years ago.
The protocol for this study was modified from
that employed in a previously reported double-
blind, placebo-controlled investigation (2). Dis-
crete lesions of similar clinical characteristics were
selected and the diagnosis was confirmed by bi-
opsy. Each lesion was outlined and numbered with
skin coloring paint to ensure that each concentra-
tion would be applied to the respective lesion
throughout the course of the study. The agents
were applied and covered with an occlusive dress-
ing daily for one month. The areas were observed
and photographed at frequent intervals. The pres-
ence of residual tumor was determined by at least
one punch biopsy of the study sites one month
following cessation of applications. The data re-
ported here were obtained by inspection of all
study sites and biopsy of any questionable areas at
the end of the first year of the observation period.
The concentrations selected for study were 20.0%,
5.0%, 0.5%, and 0.05% 5-FL in hydrophilic base.1
The 5-FL preparations were applied concurrently
to each patient. In one subject the concentration
of 5-FL was subsequently lowered to 0.005% be-
cause the 0.05% concentration had produced a
marked reaction.
RRSULTS
The gross responses observed in the basal
cell carcinomas during application of crcmc
containing the various concentrations of 5-FU
were similar but not identical in the 5 pa-
tients. Incidence of complete resolution of the
tumors as determined by clinical and/or his-
tological examination following cessation of
the application of 5-FL and at the completion
of the observation period varied in the 5 pa-
tients.
0.05% Concentration
Application of 0.05% 5-FL for one week
resulted in no gross changes or slight erythema
of the tumors. Minimal erythema usually ap-
peared by the end of the second week. Slight
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erythema persisted for a few weeks after the
applications were discontinued. No additional
changes were seen with this low concentration
in three subjects. In the other two patients an
increase in height of the tumor site and super-
ficial denudation of the involved area were
seen after the second and third week of appli-
cation, respectively.
Histological examination following cessation
of the application of 0.05% 5-FU showed per-
sistent tumor in three instances and no tumor
in two instances. Tumor resolution was not
consistently correlated with gross changes in
the tumors, since one of the tumors which re-
solved had shown only minimal erythema while
the other one had shown erythema, edema and
superficial ulceration. Similarly, two of the
tumors which were persistent had shown min-
imal erythema, while the third had shown
erytbema, edema and superficial ulceration.
Of the two sites at which tumor resolution
had been indicated by punch biopsy, one site
remained free of tumor, whereas the other site
became papular and contained basal cell car-
cinoma when rebiopsied four months later.
Of the three sites at which persistent tumor
was demonstrated by punch biopsy, one site
continued to show tumor which increased
slightly in size during observation. The other
two sites remained papular for two to three
months and then became macular. At the end
of one year, only flat, white scars approxi-
mately 2 mm. in diameter remained.
The patient (A.B.) who had shown marked
gross changes and tumor resolution with the
0.05% 5-FU was further studied with a 0.005%
5-FU preparation in an attempt to determine
the minimum concentration of 5-FU that would
not produce gross changes or tumor resolution.
Two weeks after applying 0.005% 5-FU the
tumor showed minimal erytbema which per-
sisted for some weeks after cessation of drug
administration. Histological examination
showed no persistent tumor following cessation
of the application of this low concentration of
5-FU. The site bas shown no recurrence of
tumor during the year of observation. All the
higher concentrations of 5-FU studied in this
patient had also produced tumor resolution.
0.5% Concentration
Application of 0.5% 5-PU produced more
rapid and pronounced changes than those fol-
lowing application of 0.05% 5-PU. Erythema
was present within one week of application.
After two weeks of application, increase in
height and superficial denudation were evident
in four of the five tumor sites. During the
third and fourth weeks, necrosis of tumor,
deeper ulceration and encrustation were evi-
dent.
Histological examination one month fol-
lowing cessation of 5-PU application showed
persistent tumor in two instances and absence
of tumor in three instances. The tumors which
were found to persist on histological exami-
nation had reacted grossly with marked cry-
thema and erosion.
Of the two sites which showed persistent
tumor on punch biopsy, one site continued to
show a papular tumor for three months, fol-
lowing which the tumor resolved leaving a
small, flat, white scar at the end of one year.
The other site which had been flat at the time
of punch biopsy became papular one month
later, then again became fiat two months fol-
lowing the punch biopsy and has remained flat
and grossly free of tumor. (Fig. 1)
The three sites which had initially shown
tumor resolution by punch biopsy remained
grossly free of tumor for the duration of the
observation period.
5.0% and 20.0% Concentrations
Application of 5.0% and 20.0% 5-PU prep-
arations produced gross changes that were more
rapid in onset and more marked than those
following application of the lower concen-
trations (Fig. 2). Erythema, increase in
height of the tumor site and/or surface denu-
dation appeared within the first week of appli-
cation. Ulceration of the tumor was evident
during the second week of application. During
the third and fourth weeks there was progres-
sive increase in the degree and extent of
erythema and in the area of necrosis. The dif-
ferences in responses following 5.0% and 20.0%
5-PU, respectively, were quantitative, but not
qualitative. With 20.0% 5-PU, the erythema
was more intense. Erythema and ulceration
extended beyond the area of clinically evi-
dent tumor in all five lesions to which 20.0%
5-FU preparation had been administered
(Fig. 3). With the 5.0% 5-PU preparation,
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erythema and ulceration were usually limited
to the area of gross tumor involvement (Fig.
4).
After cessation of applications of 5.0% and
Fio. 2. Superficial basal cell carcinoma to which
20.0% 5-Fl] had been applied, demonstrating more
marked reaction and scarring than that produced
by preparation containing lower concentrations of
5-FE. (a) During application of 20.0% 5-Fl], tumor
became widely ulcerated and necrotic. (b) Same as
2 (a). Pigmented, atrophic scar after completion of
application of 20.0% 5-FE.
20.0% 5-FE, histologic examination revealed
persistent tumor in one instance and no tumor
in the other nine instances. The persistent
tumor had been treated with 20.0% 5-FE and
had shown the gross changes described above
(Fig. 5). The persistent tumor slowly increased
in size during the observation period.
One of the nine sites which initially ap-
peared to be tumor free became papular and
showed basal cell carcinoma on histologic ex-
amination ten months after cessation of the
applications. The recurrent tumor had been
treated with 5% 5-FE and had reacted with
erythema and ulceration, extending in this par-
ticular site beyond the area of evident tumor.
Eight of the nine sites which had initially
shown tumor resolution remained grossly free
of tumor during observation for one year.
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FIG. 1. Superficial basal cell carcinoma to which
0.5% 5-FE was applied, demonstrating delayed
resolution of the tumor. (a) After 3 weeks of appli-
cation of 0.5% 5-FE, tumor showed erythema, ero-
sion and necrosis. (b) Same as 1 (a). Papular re-
sidual lesion, demonstrated by biopsy to contain
tumor one month after cessation of application of
creme. (e) Same as 1 (a) and 1 (b). Atrophic scar
free of tumor S months after cessation of applica-
tion of 5-FE.
DISCUSSION
The intensity and extent of the gross changes
observed in and around the basal cell carcino-
mas in this study were progressively more
marked with increasing concentrations of 5-
FTJ. The effects in regard to incidence of tumor
regressions were of the same order with the
5% and 20% preparations. The preparations
containing 5% 5-FU pr less Ite1ittIe
if any scarring since the reaction to 5-FU at
those concentrations appeared to be limited
almost entirely to the tumor. The 20.0% prep-
aration produced sufficient ulceration beyond
the site involved by tumor, so that noticeably
atrophic scarring sometimes developed. The de-
gree of grossly observed changes in the tumor,
however, did not permit reliable prediction of
FIG. 4. Superficial basal cell carcinoma to which
5.0% 5-FU had been applied, showing less marked
reaction and less scarring than that following appli-
cation of 20.0% 5-FTJ. (a) Superficial basal cell car-
cinoma before application of 5.0% 5-FU. (b) Same
as 4 (a). Scar showing minimal degree of atrophy
and pigmentation 3 months after application of
5.0% 5-F1J.
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tumor resolution at any level of concentration
of the agent.
The marked alteration in the natural course
of basal cell carcinoma incident to the local
administration of 5-FU and other chemo-
therapeutic agents has been noted before (2,
3, 6, 7). However, the delayed changes in some
of the tumor sites studied at some time fol-
lowing cessation of the administration of anti-
tumor agents have not been previously re-
ported. Four tumors to which 0.05% or
0.5% 5-FU had been administered, disappeared
clinically even though the immediate post-
treatment punch biopsies had revealed per-
sistent tumor. It is unlikely that the punch
biopsies had removed the persistent tumors
entirely, although this possibility cannot be
FIG. 3. Superficial basal cell carcinoma to which
20.0% 5-FU had been applied, showing extension of
reaction beyond the area of clinically evident tu-
mor. (a) After 3 weeks of application of 20.0% 5-
FU, marked ulceration and necrosis extending be-
yond clinically evident margin of tumor. (b) Same
as 3 (a). Pigmented scar extending beyond clinic-
ally evident margin of tumor after completion of
application.
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excluded. At one of these tumor sites, which
had been macular when biopsied, a papule
appeared subsequently and then disappeared
spontaneously, while at the other three tumor
sites a papule was present at the time of the
biopsy which persisted for one to three months
thereafter and then resolved spontaneously.
It is possible that 5-FU may exert prolonged
effiposacellcarcioaaselFastiie
eiateeffectsobservringthmeofjnistratior. Structural changes in the
nucleic acids may disrupt the genetic me-
chanics sufficiently to prevent indefinite per-
petuation of basal cell carcinoma. Repeated
recycling of 5-FU during nueleotide synthesis
may thus result in successive or cummulative
generation of defective DNA until a stage is
reached which is inconsistent with cell via-
bility. Utilization of this phenomenon might
make the regression of basal cell carcinoma
feasible without requiring acute destruction
of tumor.
Application of this principle could have
considerable advantage over techniques of
topical-chemotherapy which produce acute
tumor necrosis. Rapid destruction of large
areas of tumor can result in a variable degree
of discomfort and unsightly appearance on the
face and hands. At the present stage, the slow
resolution of tumors is not a predictable or
controllable phenomenon. The optimum con-
centration of chemotherapeutic agents, the
mode of application and the duration of
treatment will have to be studied further in
FIG. 5. Superficial basal cell carcinoma to which
20.0% 5-FU had been applied, demonstrating per
sistence of tumor despite marked reaction during
application. (a) After 3 weeks of application, tu-
mor shows erythema, necrosis and crusting. (b)
Same as 5 (a). Five months after cessation of appli-
cation, residual tumor persisted and continued to
increase in size.
TABLE I
Patient
1.E.C.
2.M.S.
3.B.L.
4MG.
5.A.B.
Evaluation 1 month after treatment Evaluation at end of study
0.05%
—
+
+
+
—
0.5%
+
—
—
+
—
5.0%
—
—
—
—
—
20.0%
—
—
+
—
—
Tumor
Resolution
3
3
2
2
4
Tumor
Persistence
1
1
2
2
0
0.05%
+
—
+
—
—
0.5%
—
—
—
—
—
5.0%
—
—
—
+
—
20.0%
—
—
+
—
—
Tumor
Resolution
3
4
2
3
4
Tumor
Persistence
1
0
2
1
0
Tumor reso-
lution
Tumor per-
sistence
2
3
3
2
5
0
4
1
14
6
3
2
5
0
4
1
4
1
16
4
(+ = tumor persistence; —= tumor resolution).
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relation to the nature of the tumor in order
to determine whether this type of chemother-
apy may be practical.
Although this and a previous study (3) in-
dicate that local chemotherapy may be of
value in eradicating large areas of multiple
basal cell epitheliomas, a regimen that will
ensure the removal of all tumors treated has
not yet been established. Residual tumor
persisted after treatment with low and high con-
centrations of 5-FU. Furthermore, in one pa-
tient, tumors were resolved with all concen-
trations of 5-FU, from 0.005% to 20.0%. Thus,
it appears that the properties of the tumor
play an important role in the response to
topical chemotherapy. Perhaps the relative
sensitivity of basal cell carcinomas to vari-
ous concentrations of anti-tumor agents should
be assayed on each patient before widespread
confluent areas of tumor arc subjected to such
agents. Even then, responsiveness may vary
from lesion to lesion in the same patient.
There is no indication in the patients we
have studied that superficial basal cell car-
cinomas of varying pathogenesis respond dif-
ferently to topically administered 5-FU. Basal
cell carcinomas arising in late radiation
change, as a result of inorganic arsenic, or in
the basal cell nevus syndrome appear to be-
have similarly.
Although no mode of topical chemotherapy
yet studied results in entirely predictable
tumor resolution, the eradication of tumors
in a large proportion of the treated areas is of
great clinical significance. Re-treatment of
residual tumors with a second course of chemo-
therapy or treatment of small areas of residual
tumor by electro-coagulation may make large
confluent areas of basal cell carcinomas or
solar keratoses more amenable to eradication
than with the standard methods.N evnnaa
of antitumor drug action and such factors as
frequency, duration and manner of application
and nature of the vehicle. Comparative stud-
ies on the parameters of topical chemotherapy
arc, therefore, being carried out on discrete
lesions and on large areas involved diffusely
by basal cell carcinoma or solar keratoses.
5UMMARY
The topical application of four concentra-
tions (0.05%, 0.5%, 5.0%, 20.0%) of 5-Flu-
orouracil ointment to twenty discrete superfi-
cial basal cell carcinomas produced changes in
the natural course of the tumors. These changes
were progressively more intense with increas-
ing concentrations of 5-FTJ. The degree of
grossly observed changes in the tumors did not
necessarily correlate with tumor resolution.
Delayed chemothcrapcutic effects were ob-
served, resulting in tumor resolution several
months after discontinuing topical adminis-
tration of the anti-tumor agent.
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